2013
DOI: 10.4103/1119-3077.116871
|View full text |Cite
|
Sign up to set email alerts
|

The end of the road for prostate specific antigen testing?

Abstract: Many candidate biomarkers for diagnosis of prostate cancer have been investigated, but prostate-specific antigen (PSA) testing remains the frontline test for both mass screening and individual clinical testing. Although the PSA test is cost-effective, analytically reliable, and flexibly high throughput, it has a very weak correlation with prostate malignancy. This has resulted in over-diagnosis and over-treatment of patients leading to costly economic, social, and psychological impacts. PSA testing lacks the a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2015
2015
2016
2016

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 95 publications
0
0
0
Order By: Relevance
“…So, lack of specificity and sensitivity limited its use as a screening tool in the general population. 6,7 There is therefore still an urgent need for non-invasive biomarkers for the detection of PCa.…”
Section: Introductionmentioning
confidence: 99%
“…So, lack of specificity and sensitivity limited its use as a screening tool in the general population. 6,7 There is therefore still an urgent need for non-invasive biomarkers for the detection of PCa.…”
Section: Introductionmentioning
confidence: 99%